KAS
GANX icon

Kestra Advisory Services’s Gain Therapeutics GANX Stock Holding History

Kestra Advisory Services’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.3K Hold
12,000
– – ﹤0.01% 3089
2025
Q4 		$38.6K Hold
12,000
– – ﹤0.01% 4124
2025
Q3 		$21.2K Buy
+12,000
New +$20.2K ﹤0.01% 2882

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Kestra Advisory Services's GANX Position: Q1 2026 in Review

Kestra Advisory Services held its Gain Therapeutics (GANX) position steady in Q1 2026 at 12,000 shares worth $23.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3089.

Kestra Advisory Services first reported a position in GANX in Q3 2025 and has held it in 3 quarters since. The position peaked at $38.6K in Q4 2025. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

  • Kestra Advisory Services held 12,000 shares of Gain Therapeutics worth $23.3K as of Q1 2026.
  • Kestra Advisory Services left its Gain Therapeutics share count unchanged in Q1 2026.
  • Gain Therapeutics made up ﹤0.01% of Kestra Advisory Services's portfolio in Q1 2026, its #3089 holding.
  • Kestra Advisory Services first reported a position in Gain Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Kestra Advisory Services's Gain Therapeutics position peaked at $38.6K in Q4 2025.
  • 42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Kestra Advisory Services's 13F filing for Q1 2026, filed 30 Apr 2026.